Contract Development & Manufacturing, Discovery-to-Commercial Outsourcing, Integrated CRAMS
CDMO / CRAMS
Executive Search
55+ CDMO / CRAMS Placements — with an average 89 Days time-to-placement and a 12-month candidate guarantee.
55+
CDMO / CRAMS Placements
89 Days
Avg. Time-to-Placement
91%
Offer Acceptance Rate
12 Months
Candidate Guarantee
Specialisation withinPharmaceuticals & Biotechnology·Innovating for Better Health
CDMO / CRAMS (Contract Development and Manufacturing Organisations / Contract Research and Manufacturing Services) is the discovery-to-commercial outsourcing tranche of the pharma value chain and one of the fastest-growing export-oriented sub-sectors in Indian pharma. The ecosystem spans listed and privately-held integrated CDMOs (the market-leading listed discovery-to-commercial CDMO, the CDMO arms of listed custom-synthesis-and-API operators and listed large-cap pharma majors, listed pharmaceutical-solutions groups' CDMO businesses, listed complex-API-and-CDMO specialists, listed API-and-CDMO specialists, PE-backed privately-held integrated CDMOs, and global CDMO operators' India businesses), discovery-focused CROs with contract-manufacturing capability, API and intermediates CDMOs, formulations CDMOs (oral-solid-dose, injectables, lyophilised, sterile fill-and-finish), biologics CDMOs (mAb, fusion-protein, microbial-fermentation), peptide and oligonucleotide CDMOs, HPAPI (Highly Potent API) specialists, and emerging cell-and-gene-therapy CDMOs. Leadership here requires fluency in integrated discovery-to-commercial project-delivery, USFDA-and-EMA-and-PMDA inspection readiness, client-stewardship with Big Pharma and emerging-biotech innovators, multi-site campaign-and-capacity planning, and the specific milestone-and-royalty-economics rhythm of CDMO contracts.
Is This Your Situation?
If any of these sound familiar, you're speaking to the right practice.
→Listed integrated CDMO running MD succession — confidential search with promoter and nomination-committee alignment across integrated discovery-to-commercial CDMO operating credibility, Big-Pharma-and-biotech-innovator client-stewardship, and listed-group governance.
→PE-backed multi-site CDMO preparing for an IPO hiring a President / COO to industrialise multi-modality operations and deliver a 4-6 quarter IPO readiness plan.
→CDMO operator scaling its peptide-and-oligonucleotide business (GLP-1-class demand) hiring a Head of CDMO with peptide-synthesis-and-scale-up credibility and Big-Pharma-and-biotech-innovator relationship depth.
→Multi-site CDMO running Site Head succession for its flagship USFDA-inspected site — leaders with zero-483-inspection-readiness credibility and multi-product-and-multi-client site-operations discipline.
Our CDMO / CRAMS Track Record
Situation:
A PE-backed multi-site integrated CDMO preparing for an IPO needed President / COO succession. The brief required integrated CDMO operating credibility, multi-modality (small-molecule, biologics, peptide, HPAPI) capacity industrialisation discipline, Big-Pharma-client stewardship, and an IPO-readiness operating rhythm across 4-6 quarters.
Outcome:
Placed a President / COO with prior President-of-CDMO-division tenure at a listed integrated CDMO and subsequent global-CDMO-operations tenure at a multi-geography CDMO. The PE-backed CDMO's IPO-readiness plan delivered on schedule with multi-modality capacity industrialisation and Big-Pharma-client expansion within 18 months of the President's joining.
Situation:
A listed integrated CDMO scaling its peptide-and-oligonucleotide capability on the back of GLP-1-class demand needed Head of CDMO succession. The brief required integrated-service-offering credibility, peptide-and-oligonucleotide-synthesis scale-up discipline, Big-Pharma-and-biotech-innovator relationship depth, and MSA-and-milestone-contract-negotiation fluency.
Outcome:
Placed a Head of CDMO with prior head-of-innovator-services tenure at a global CDMO and subsequent multi-modality leadership tenure at an Indian listed CDMO. Peptide-and-oligonucleotide CDMO revenue compounded materially with multiple Big-Pharma-and-biotech-innovator MSAs signed within 12 months of the Head's joining.
All client details anonymised. Specific mandates available for reference under NDA upon request.
Our CDMO / CRAMS Practice
CDMO / CRAMS (Contract Development and Manufacturing Organisations / Contract Research and Manufacturing Services) is the discovery-to-commercial outsourcing tranche of the pharma value chain and one of the fastest-growing export-oriented sub-sectors in Indian pharma. The ecosystem spans listed and privately-held integrated CDMOs (the market-leading listed discovery-to-commercial CDMO, the CDMO arms of listed custom-synthesis-and-API operators and listed large-cap pharma majors, listed pharmaceutical-solutions groups' CDMO businesses, listed complex-API-and-CDMO specialists, listed API-and-CDMO specialists, PE-backed privately-held integrated CDMOs, and global CDMO operators' India businesses), discovery-focused CROs with contract-manufacturing capability, API and intermediates CDMOs, formulations CDMOs (oral-solid-dose, injectables, lyophilised, sterile fill-and-finish), biologics CDMOs (mAb, fusion-protein, microbial-fermentation), peptide and oligonucleotide CDMOs, HPAPI (Highly Potent API) specialists, and emerging cell-and-gene-therapy CDMOs. Leadership here requires fluency in integrated discovery-to-commercial project-delivery, USFDA-and-EMA-and-PMDA inspection readiness, client-stewardship with Big Pharma and emerging-biotech innovators, multi-site campaign-and-capacity planning, and the specific milestone-and-royalty-economics rhythm of CDMO contracts.
We place leaders across listed integrated CDMOs, privately-held and PE-backed CDMOs, API and intermediates CDMOs, formulations and sterile CDMOs, biologics and peptide CDMOs, and HPAPI specialists. Engagements include CEO / MD searches for listed integrated CDMOs, President / COO placements, Head of CDMO / Head of CRAMS searches, Head of Business Development (CDMO) placements, Head of Operations / Head of Manufacturing / Site Head placements, Head of Quality / Head of Regulatory Affairs searches, and CFO placements with CDMO-contract-and-milestone-accounting credibility. Every mandate is retained and closed-network.
As a specialist CEO mandates in listed CDMOs, our practice also covers COO placements in multi-site CDMOs, our practice also covers Pharmaceuticals & Biotech practice overview, and as a source for Pharmaceuticals — API & bulk drugs leadership.
The CDMO / CRAMS Landscape Today
India's CDMO / CRAMS export revenue has crossed $18-20 billion with structural tailwinds from the China+1 supply-diversification theme, Big Pharma patent-cliff-and-innovator-outsourcing trend, PLI-Bulk-Drug and PLI-Medical-Devices schemes, and emerging biotech-innovator client demand. The market-leading listed discovery-to-commercial CDMO (promoted by a listed biosimilars parent), the CDMO arms of listed custom-synthesis-and-API operators and listed large-cap pharma majors, listed pharmaceutical-solutions groups' CDMO businesses (promoted by a diversified conglomerate), listed complex-API-and-CDMO specialists, listed API-and-CDMO specialists, PE-backed privately-held integrated CDMOs, and global CDMO operators' India businesses are the largest India-headquartered integrated CDMOs. The US-and-EU Big Pharma client cohort — covering the top-10 global-pharma majors — accounts for the majority of India's CDMO export revenue, with emerging biotech innovators and specialty-pharma operators providing the high-growth tranche. USFDA, EMA, PMDA, and MHRA inspection readiness is central — successful CDMOs maintain zero-483 / zero-warning-letter inspection track records across multiple sites. Multi-year MSA (Master Service Agreement), milestone-linked-and-royalty-bearing contract architecture, and client-stewardship across Big-Pharma-and-biotech-innovator relationships are the defining operating disciplines. HPAPI (oncology, hormonal, and immuno-suppressant molecules with OEB-4 / OEB-5 potency), peptide-and-oligonucleotide synthesis (GLP-1-class molecules driving the current surge), and cell-and-gene-therapy CDMO capability are the fastest-growing high-value tranches. Leadership in the sub-sector requires fluency in integrated discovery-to-commercial project-delivery, regulated-markets inspection readiness, client-stewardship with Big Pharma and biotech innovators, multi-site campaign-and-capacity planning, and the specific milestone-and-royalty-economics rhythm of CDMO contracts. Compensation is at the upper end of Indian pharma bands with material US-dollar-linked performance architecture.
Key Leadership Challenges in CDMO / CRAMS
CEO / MD succession for listed integrated CDMOs — leaders with integrated discovery-to-commercial CDMO operating credibility, Big-Pharma-and-biotech-innovator client-stewardship, multi-site regulated-markets inspection-readiness, and the governance rhythm of listed CDMO operators.
President / COO placements for multi-site CDMO operators — leaders running integrated CDMO P&Ls with multi-modality (small-molecule, biologics, peptide, HPAPI) capability and multi-geography (India, US, EU) site stewardship.
Head of CDMO / Head of CRAMS placements — leaders with integrated-service-offering credibility, Big-Pharma-client relationship depth, and multi-modality capacity-and-campaign planning discipline.
Head of Business Development (CDMO) placements — CDMO operators need BD Heads with Big-Pharma-and-biotech-innovator relationship depth, MSA-and-milestone-contract-negotiation credibility, and the specific RFP-to-contract-close rhythm of CDMO BD.
Head of Operations / Head of Manufacturing / Site Head placements — multi-site CDMOs need Site Heads with USFDA-and-EMA-inspection-readiness credibility, campaign-and-capacity-planning discipline, and the specific multi-product-and-multi-client site-operations architecture.
Head of Quality / Head of Regulatory Affairs placements — CDMOs need QA-and-RA Heads with zero-483-inspection-readiness credibility, DMF-and-CEP-and-ANDA submission discipline, and the specific multi-regulatory-agency (USFDA, EMA, PMDA, MHRA) stewardship architecture.
What We Look For in CDMO / CRAMS Leaders
Across mandates, cdmo / crams leadership tends to cluster into a small set of archetypes. We calibrate each search against the profile your board actually needs — not the one most commonly available.
The Listed CDMO MD / President
Executive who has run a listed integrated CDMO or multi-geography CDMO group — fluent in integrated discovery-to-commercial CDMO operating credibility, Big-Pharma-and-biotech-innovator client-stewardship, multi-site regulated-markets inspection-readiness, and the governance rhythm of listed CDMO operators.
The Multi-Site COO / President (CDMO)
Operator who has run multi-site and multi-modality CDMO P&Ls — fluent in campaign-and-capacity-planning across small-molecule, biologics, peptide, and HPAPI modalities, multi-geography (India, US, EU) site stewardship, and multi-client multi-product operations discipline.
The Head of CDMO / Head of CRAMS
Segment leader with integrated-service-offering credibility, Big-Pharma-client relationship depth, multi-modality capacity-and-campaign planning discipline, and the specific innovator-outsourcing rhythm of CDMO operations. Often a chemistry or pharma-engineering graduate with subsequent Head of CDMO or Head of Innovator-Services leadership.
The BD / Client-Services Head (CDMO)
Commercial leader with Big-Pharma-and-biotech-innovator relationship depth, MSA-and-milestone-contract-negotiation credibility, RFP-to-contract-close rhythm fluency, and the specific client-stewardship-and-account-management architecture of CDMO BD.
The Site Head / Head of Manufacturing (CDMO)
Operations leader with USFDA-and-EMA-inspection-readiness credibility, campaign-and-capacity-planning discipline, multi-product-and-multi-client site-operations architecture fluency, and the specific GMP-and-technical-operations rhythm of CDMO sites.
The QA / RA Head (CDMO)
Compliance leader with zero-483-inspection-readiness credibility, DMF-and-CEP-and-ANDA submission discipline, multi-regulatory-agency (USFDA, EMA, PMDA, MHRA) stewardship, and the specific GMP-and-data-integrity-and-CSV (Computer System Validation) architecture of regulated CDMO operations.
The CDMO CFO
Finance leader with CDMO-contract-and-milestone-accounting credibility, multi-currency (US-dollar-and-euro) receivables stewardship, capex-and-campaign-cost discipline, and the specific investor-communication architecture of listed or IPO-bound CDMO operators.
Regulatory & Compensation Context
Regulatory Backdrop
CDMO operations sit at the intersection of USFDA, EMA, PMDA, MHRA, WHO-GMP, and CDSCO regulatory architectures. The 21 CFR Part 211 (GMP) and 21 CFR Part 11 (electronic-records-and-signatures) frameworks govern USFDA-inspected sites; the EU GMP (EudraLex Volume 4) framework governs EMA-inspected sites. DMF (Drug Master File), CEP (Certificate of Suitability), ANDA (Abbreviated New Drug Application), and MA (Marketing Authorisation) submission architectures are the primary regulatory dossiers. ICH Q7 (GMP for APIs), ICH Q8 / Q9 / Q10 (Pharmaceutical Development, Quality Risk Management, Pharmaceutical Quality System), and ICH Q11 (Development and Manufacture of Drug Substances) provide the integrated quality architecture. Data integrity (ALCOA+ principles) and CSV (Computer System Validation) are the most common inspection-finding areas. The PLI-Bulk-Drug scheme (₹6,940 crore outlay, 41 fermentation-and-chemistry-based products) incentivises domestic CDMO capacity for APIs; the PLI-Medical-Devices and PLI-Pharmaceuticals schemes provide adjacent incentives. Export-control, customs-and-SEZ, and technology-transfer architectures add operational complexity for multi-geography CDMOs.
Compensation Architecture
CDMO leadership compensation is at the upper end of Indian pharma bands with material US-dollar-linked performance architecture. Listed-integrated-CDMO MD compensation ranges ₹8-20 crore fixed with multi-year ESOP / PSU (Performance Share Unit) architectures; Big-Pharma-client BD Head compensation can cross ₹6 crore with MSA-win-and-contract-value-linked variable; Site Head compensation for a flagship USFDA-inspected site ranges ₹2.5-5 crore; CFO compensation for a listed or IPO-bound CDMO ranges ₹4-9 crore with IPO-readiness and investor-communication-linked performance architecture.
Roles We Typically Place
Why Gladwin International Leadership Advisors for CDMO / CRAMS
CEO / MD searches for listed and privately-held integrated CDMOs.
President / COO placements for multi-site and multi-modality CDMOs.
Head of CDMO / Head of CRAMS / Head of Innovator-Services placements.
Head of Business Development (CDMO) / Head of Client-Services placements.
Head of Operations / Head of Manufacturing / Site Head placements.
Head of Quality / Head of Regulatory Affairs / Head of Technical Operations placements.
CFO and Head of IR placements with CDMO-contract-and-milestone-accounting credibility.
Organisations We Serve
Listed integrated CDMOs (the market-leading listed discovery-to-commercial CDMO, CDMO arms of listed custom-synthesis-and-API operators, listed pharmaceutical-solutions groups' CDMO businesses, and listed complex-API-and-CDMO specialists)
PE-backed integrated CDMOs
Multi-geography integrated CDMOs and global CDMO operators' India businesses
API and intermediates CDMOs
Formulations and sterile-fill-finish CDMOs
Biologics, peptide, and oligonucleotide CDMOs
HPAPI (Highly Potent API) specialists
Emerging cell-and-gene-therapy CDMOs
CDMO / CRAMS leaders assessed on the Pharma & Biotech “HELIX” framework
Eight dimensions calibrated for pharmaceutical and biotechnology leadership. Dimensions are calibrated for cdmo / crams mandates where relevant.
Parent Practice
Return to Pharmaceuticals & Biotechnology
Discuss a CDMO / CRAMS Mandate
Confidential · No obligation
Response within 4 business hours · All enquiries handled by a senior practice partner · Strictly confidential